Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 623732, 7 pages
http://dx.doi.org/10.1155/2015/623732
Clinical Study

Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade “A” Success Rate for First-Line Helicobacter pylori Eradication

1Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung District, Kaohsiung City 833, Taiwan
2Division of Infectious Diseases, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung District, Kaohsiung City 833, Taiwan
3Division of Internal Medicine, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 123 Ta-Pei Road, Niao-Sung District, Kaohsiung City 833, Taiwan

Received 4 December 2014; Accepted 10 January 2015

Academic Editor: Khean-Lee Goh

Copyright © 2015 Wei-Chen Tai et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Malfertheiner, F. Megraud, C. A. O'Morain et al., “Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report,” Gut, vol. 61, no. 5, pp. 646–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. D. C. Wu, P. I. Hsu, J. Y. Wu et al., “Sequential and concomitant therapy with four drugs is equally effective for eradication of H. pylori infection,” Clinical Gastroenterology and Hepatology, vol. 8, no. 1, pp. 36–41, 2010. View at Publisher · View at Google Scholar
  3. J.-M. Liou, C.-C. Chen, M.-J. Chen et al., “Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial,” The Lancet, vol. 381, no. 9862, pp. 205–213, 2013. View at Publisher · View at Google Scholar
  4. S. K. Poon, C. S. Chang, J. Su et al., “Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies,” Alimentary Pharmacology and Therapeutics, vol. 16, no. 2, pp. 291–296, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. W. L. Chang, B. S. Sheu, H. C. Cheng, Y. J. Yang, H. B. Yang, and J. J. Wu, “Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan,” Journal of Gastroenterology and Hepatology, vol. 24, no. 7, pp. 1230–1235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. C. T. Hu, C. C. Wu, C. Y. Lin et al., “Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan,” Journal of Gastroenterology and Hepatology, vol. 22, pp. 720–723, 2007. View at Google Scholar
  7. Y. J. Yang, J. C. Yang, Y. M. Jeng, M. H. Chang, and Y. H. Ni, “Prevalence and rapid identification of clarithromycin-resistant Helicobacter pylori isolates in children,” Pediatric Infectious Disease Journal, vol. 20, no. 7, pp. 662–666, 2001. View at Publisher · View at Google Scholar · View at Scopus
  8. M.-C. Chen, W.-Y. Lei, J.-S. Lin et al., “Levofloxacin-amoxicillin/clavulanate-rabeprazole versus a standard seven-day triple therapy for eradication of Helicobacter pylori infection,” BioMed Research International, vol. 2014, Article ID 158520, 7 pages, 2014. View at Publisher · View at Google Scholar
  9. C. H. Kuo, F. C. Kuo, H. M. Hu et al., “The optimal first-line therapy of Helicobacter pylori infection in year 2012,” Gastroenterology Research and Practice, vol. 2012, Article ID 168361, 8 pages, 2012. View at Publisher · View at Google Scholar
  10. C. O'Morain, T. Borody, A. Farley et al., “Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study,” Alimentary Pharmacology and Therapeutics, vol. 17, no. 3, pp. 415–420, 2003. View at Publisher · View at Google Scholar · View at Scopus
  11. L. Laine, R. Hunt, H. EI-Zimaity, B. Nguyen, M. Osato, and J. Spénard, “Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a prospective, randomized, multicenter, North American trial,” The American Journal of Gastroenterology, vol. 98, no. 3, pp. 562–567, 2003. View at Publisher · View at Google Scholar · View at Scopus
  12. F.-W. Tsay, H. H. Tseng, P.-I. Hsu et al., “Sequential therapy achieves a higher eradication rate than standard triple therapy in Taiwan,” Journal of Gastroenterology and Hepatology, vol. 27, no. 3, pp. 498–503, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. W. H. Choi, D. I. Park, S. J. Oh et al., “Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea,” The Korean Journal of Gastroenterology, vol. 51, no. 5, pp. 280–284, 2008. View at Google Scholar · View at Scopus
  14. J. W. Lee, N. Kim, J. M. Kim et al., “A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea,” Scandinavian Journal of Gastroenterology, vol. 49, no. 8, pp. 917–924, 2014. View at Publisher · View at Google Scholar
  15. L. Zhou, J. Zhang, M. Chen et al., “A comparative study of sequential therapy and standard triple therapy for Helicobacter pylori infection: a randomized multicenter trial,” The American Journal of Gastroenterology, vol. 109, no. 4, pp. 535–541, 2014. View at Publisher · View at Google Scholar · View at Scopus
  16. P. I. Hsu, D. C. Wu, J. Y. Wu, and D. Y. Graham, “Modified sequential Helicobacter pylori herapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days,” Helicobacter, vol. 16, no. 2, pp. 139–145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  17. D. H. Oh, D. H. Lee, K. K. Kang et al., “The efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy,” Journal of Gastroenterology and Hepatology, vol. 29, no. 6, pp. 1171–1176, 2014. View at Publisher · View at Google Scholar · View at Scopus
  18. H. Sardarian, H. Fakheri, V. Hosseini, T. Taghvaei, I. Maleki, and M. Mokhtare, “Comparison of hybrid and sequential therapies for helicobacter pylori eradication in Iran: a prospective randomized trial,” Helicobacter, vol. 18, no. 2, pp. 129–134, 2013. View at Publisher · View at Google Scholar · View at Scopus
  19. A. G. McNicholl, A. C. Marin, J. Molina-Infante et al., “Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice,” Gut, vol. 63, no. 2, pp. 244–249, 2014. View at Publisher · View at Google Scholar · View at Scopus
  20. Y.-K. Huang, M.-C. Wu, S. S. Wang et al., “Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication,” Journal of Digestive Diseases, vol. 13, no. 4, pp. 232–238, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Molina-Infante, C. Pazos-Pacheco, G. Vinagre-Rodriguez et al., “Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resist ant strains,” Helicobacter, vol. 17, no. 4, pp. 269–276, 2012. View at Publisher · View at Google Scholar · View at Scopus
  22. S. D. Georgopoulos, E. Xirouchakis, B. Martinez-Gonzalez et al., “Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area,” Helicobacter, vol. 18, no. 6, pp. 459–467, 2013. View at Publisher · View at Google Scholar · View at Scopus
  23. S. Georgopoulos, V. Papastergiou, E. Xirouchakis et al., “Nonbismuth quadruple ‘concomitant’ therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. Pylori eradication: a randomized trial,” Journal of Clinical Gastroenterology, vol. 47, no. 3, pp. 228–232, 2013. View at Publisher · View at Google Scholar · View at Scopus
  24. J. Heo, S. W. Jeon, J. T. Jung et al., “A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication,” Digestive and Liver Disease, vol. 46, no. 11, pp. 980–984, 2014. View at Publisher · View at Google Scholar
  25. S. K. Chuah, P. I. Hsu, K. C. Chang et al., “Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori,” Helicobacter, vol. 17, no. 3, pp. 216–223, 2012. View at Publisher · View at Google Scholar · View at Scopus
  26. W. C. Tai, C. H. Lee, S. S. Chiou et al., “The clinical and bacteriological factors for optimal levofloxacin-containing triple therapy in second-line Helicobacter pylori eradication,” PLoS ONE, vol. 9, no. 8, Article ID e105822, 2014. View at Publisher · View at Google Scholar
  27. C.-M. Liang, J.-W. Cheng, C.-M. Kuo et al., “Levofloxacin-containing second-line anti-Helicobacter pylori eradication in Taiwanese real-world practice,” Biomedical Journal, vol. 37, no. 5, pp. 326–330, 2014. View at Publisher · View at Google Scholar
  28. S. K. Chuah, W. C. Tai, P. I. Hsu et al., “The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment—a Pilot Study,” Helicobacter, vol. 17, no. 5, pp. 374–381, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. P. I. Hsu, I. R. Hwang, D. Cittelly et al., “Clinical presentation in relation to diversity within the Helicobacter pylori cag pathogenicity island,” The American Journal of Gastroenterology, vol. 97, no. 9, pp. 2231–2238, 2002. View at Publisher · View at Google Scholar · View at Scopus
  30. P. I. Hsu, D. C. Wu, W. C. Chen et al., “Comparison of 7-day triple, 10-day sequential and 7-day concomitant therapies for Helicobacter pylori infection—a randomized controlled trial,” Antimicrobial Agents and Chemotherapy, vol. 58, no. 10, pp. 5936–5942, 2014. View at Publisher · View at Google Scholar
  31. V. Papastergiou, S. D. Georgopoulos, and S. Karatapanis, “Treatment of Helicobacter pylori infection: meeting the challenge of antimicrobial resistance,” World Journal of Gastroenterology, vol. 20, no. 29, pp. 9898–9911, 2014. View at Publisher · View at Google Scholar